Quarterly ResultJul 28, 2026, 04:37 PM
Chemed Q2 Revenue $673.3M, EPS $5.13; Raises Full-Year Guidance
AI Summary
Chemed Corporation reported strong financial results for the second quarter of 2026, with consolidated revenue increasing by 8.8% and GAAP diluted EPS rising by 43.7%. The VITAS segment showed significant outperformance, leading to an upward revision of the company's full-year guidance for adjusted diluted EPS. The Roto-Rooter segment also contributed positively with a 3.3% revenue increase.
Key Highlights
- Consolidated revenue increased 8.8% to $673.3 million.
- GAAP Diluted Earnings-per-Share (EPS) rose 43.7% to $5.13.
- Adjusted Diluted EPS increased 41.9% to $6.06.
- VITAS segment net patient revenue grew 11.9% to $443.3 million.
- Roto-Rooter segment revenue increased 3.3% to $229.9 million.
- Full-year 2026 adjusted diluted EPS guidance raised to $25.00-$25.75.
- Company repurchased 210,000 shares for $89.8 million in Q2 2026.
Price Impact
More from CHE